NasVax Ltd. | Date: 2010-02-16
vaccines; vaccine stabilizers; adjuvants for vaccines; adjuvants for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious diseases, bacteria-based diseases, viral diseases and of non-infectious diseases, namely, cancer, Alzheimers disease, addiction, auto-immune disorders, allergy; anti-infective preparations; antiviral preparations; antifungal preparations; nasal spray preparations; drug delivery agents consisting of compounds that facilitate delivery of a wide range of biologicals, vaccines and pharmaceuticals; combination vaccines, namely, conjugate vaccines for use with other vaccines; pharmaceutical preparations, namely, immunomodulators, antibodies, haptens and glycosaccharide antigen mimitopes for the prevention and treatment of infectious diseases, cancer, Alzheimers disease, addiction, auto-immune disorders, allergy.
Halota W.,Nicolaus Copernicus University |
Ferenci P.,Vienna University Hospital |
Kozielewicz D.,Nicolaus Copernicus University |
Dybowska D.,Nicolaus Copernicus University |
And 5 more authors.
Journal of Viral Hepatitis | Year: 2015
Orally administered anti-CD3 antibodies are biologically active in the gut through induction of regulatory T cells, exert an immune-modulatory effect, and alleviate insulin resistance and liver damage in patients with NASH. Aims: To determine the safety of oral anti-CD3 monoclonal antibody (MAb) immunotherapy in chronic HCV patients with associated immune dysfunction. Methods: Four groups (n = 9) of chronic HCV patients who were nonresponders to interferon plus ribavirin therapy received oral placebo (group A) or anti-CD3 MAb at one of three dosage levels for 30 days. Patients were followed for safety parameters and serum levels of liver enzymes, virus, cytokines and regulatory T cells. Results: Oral anti-CD3 immunotherapy was safe and well tolerated; no treatment-related adverse events were noted. The following improvements were noted relative to pretreatment levels: HCV viral load and AST and ALT levels decreased in the low- and high-dose groups following 30 days of therapy. In two of the treated groups, an increase in regulatory T cells (CD4+ CD25+) was noted. The positive effects were somewhat more apparent in subjects with initially elevated liver enzyme levels. Conclusions: Oral anti-CD3 MAb immunotherapy for nonresponder HCV patients was safe and well tolerated. Trends and statistically significant improvements were observed as reductions in viral load and liver enzyme levels, along with an increase in regulatory T-cell levels. These data support a role for the immune system in the pathogenesis of HCV infection and suggest that this immunotherapy is worthy of evaluation in combination with HCV antiviral drugs. © 2014 John Wiley & Sons Ltd. Source
Hadasit Medical Research Services & Decvelopment Co. and Nasvax Ltd. | Date: 2011-04-29
A method or composition comprising an anti-CD3 immune molecule for treatment of hepatitis in a subject.
Streptococcus pneumoniae cell-wall-localized phosphoenolpyruvate protein phosphotransferase can function as an adhesin: Identification of its host target molecules and evaluation of its potential as a vaccine
Nebenzahl Y.M.,Soroka University Medical Center |
Nebenzahl Y.M.,Ben - Gurion University of the Negev |
Blau K.,Soroka University Medical Center |
Blau K.,Ben - Gurion University of the Negev |
And 36 more authors.
PLoS ONE | Year: 2016
In Streptococcus pneumonia, phosphoenolpyruvate protein phosphotransferase (PtsA) is an intracellular protein of the monosaccharide phosphotransferase systems. Biochemical and immunostaining methods were applied to show that PtsA also localizes to the bacterial cell-wall. Thus, it was suspected that PtsA has functions other than its main cytoplasmic enzymatic role. Indeed, recombinant PtsA and anti-rPtsA antiserum were shown to inhibit adhesion of S. pneumoniae to cultured human lung adenocarcinoma A549 cells. Screening of a combinatorial peptide library expressed in a filamentous phage with rPtsA identified epitopes that were capable of inhibiting S. pneumoniae adhesion to A549 cells. The insert peptides in the phages were sequenced, and homologous sequences were found in human BMPER, multimerin1, protocadherin 19, integrinβ4, epsin1 and collagen type VIIa1 proteins, all of which can be found in A549 cells except the latter. Six peptides, synthesized according to the homologous sequences in the human proteins, specifically bound rPtsA in the micro-molar range and significantly inhibited pneumococcal adhesion in vitro to lung- and tracheal-derived cell lines. In addition, the tested peptides inhibited lung colonization after intranasal inoculation of mice with S. pneumoniae. Immunization with rPtsA protected the mice against a sublethal intranasal and a lethal intravenous pneumococcal challenge. In addition, mouse anti rPtsA antiserum reduced bacterial virulence in the intravenous inoculation mouse model. These findings showed that the surface-localized PtsA functions as an adhesin, PtsA binding peptides derived from its putative target molecules can be considered for future development of therapeutics, and rPtsA should be regarded as a candidate for vaccine development. © 2016 Mizrachi Nebenzahl et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Source
Lalazar G.,Hebrew University of Jerusalem |
Lalazar G.,Yeshiva University |
Mizrahi M.,Hebrew University of Jerusalem |
Turgeman I.,Hebrew University of Jerusalem |
And 13 more authors.
Journal of Clinical Immunology | Year: 2015
ᅟ: Oral administration of anti-CD3 antibodies induced regulatory T cells (Tregs) alleviating the insulin resistance and liver damage in animal models. Objective: To determine the safety and biological effects of oral OKT3 monoclonal antibody (Balashov et al. Neurology 55:192–8, 2000) in patients with NASH. Design: In this Phase-IIa trial, four groups of patients with biopsy-proven NASH (n = 9/group) received placebo (group A) or oral OKT3 (group B: 0.2; C: 1.0; D: 5.0 mg/day) for 30 days. Patients were followed for safety, liver enzymes, glucose, lipid profile, oral glucose tolerance test (OGTT), serum cytokines and Tregs. Results: Oral OKT3 was well tolerated without treatment-related adverse events. OKT3 induced Tregs: with significant increases of CD4+LAP+ (Latency associated peptide) and CD4+CD25+LAP+ cells in Group D, and a significant increase in TGF-β in Groups C and D. AST decreased significantly in group D and a trend in Groups B and C. Fasting plasma glucose decreased significantly in all treatment groups compared with placebo. OGTT decreased significantly in Group D. Correlations were observed between the changes in several immune-modulatory effects and clinical biomarkers. While serum anti-CD3 levels where undetectable increases in human anti-mouse antibody levels were observed in Groups C and D. Conclusion: Oral administration of anti-CD3 MAb to patients with NASH was safe and well tolerated. Positive biological effects were noted in several hepatic, metabolic and immunologic parameters. These findings provide the basis for future trials to investigate the effect of oral anti-CD3 MAb immunotherapy in patients with NASH. © 2015, Springer Science+Business Media New York. Source